Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Unknown 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 47OTHER 22OTHER_GOV 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Other solid neoplasm 1NET 1Lymphoid 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Triple Negative Breast Neoplasms 2Stomach Neoplasms 1Intestinal Neoplasms 1HER2 Low Breast Carcinoma 1Breast Neoplasms 1

Interventions

Tamoxifen 10Capecitabine 10Trastuzumab 9Docetaxel 9pyrotinib 7Exercise 7Control Groups 7Vinorelbine 6Paclitaxel 6Letrozole 6Gemcitabine 6Cyclophosphamide 6Carboplatin 6exemestane 5Indocyanine Green 5Anastrozole 5pertuzumab 4dalpiciclib 4Injections 4Fulvestrant 4Doxorubicin 4Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3Radiation 3Mammography 3Epirubicin 3Drug Therapy 3Cisplatin 3Bevacizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER_GOV × Injections × Breast × Clear all
NCT05911958 2024-11-04

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
66 enrolled
Breast

HER2 Low Breast Carcinoma

NCT06078670 2023-10-12

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Fujian Cancer Hospital

Phase 1/2 Not yet recruiting
96 enrolled
BreastGastrointestinal

Intestinal Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Henan Cancer Hospital

Phase 1/2 Unknown
39 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Instituto Nacional de Cancer, Brazil

Phase 2 Unknown
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡